Volume

Acquisition of drug resistance in endothelial cells by tumor-derived extracellular vesicles and cancer progression

Targeting T regulatory (T<sub>reg</sub>) cells in immunotherapy-resistant cancers

Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel

Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer

Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia

Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors

Leveraging genomics, transcriptomics and epigenomics to understand chemoimmunotherapy resistance in chronic lymphocytic leukemia

Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implications

Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer

Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model

Dysregulation of calcium homeostasis in cancer and its role in chemoresistance

Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells

The therapeutic potential of circular RNA in triple-negative breast cancer

HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs

Emerging role of MYB transcription factors in cancer drug resistance

Isocucurbitacin B inhibits glioma growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286a

Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers

Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them

Chemosensitizing effect of pentoxifylline in sensitive and multidrug-resistant non-small cell lung cancer cells

ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients

Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer

The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer

Recent advanced lipid-based nanomedicines for overcoming cancer resistance

Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects

Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review

Impact of genetic variants in the solute carrier (<i>SLC</i>) genes encoding drug uptake transporters on the response to anticancer chemotherapy

Targeting NETosis: nature’s alarm system in cancer progression

The uniqueness of ABCB5 as a full transporter ABCB5FL and a half-transporter-like ABCB5β

The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer

Research progress on the role and mechanism of circular RNA in drug resistance of head and neck squamous cell carcinoma

Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer

Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment

Non-coding RNA and drug resistance in head and neck cancer

Intercellular transfer of multidrug resistance mediated by extracellular vesicles

Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions <i>in vitro</i>

Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy

Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers

Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies

The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models

NFE2L2 and ferroptosis resistance in cancer therapy

Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma

The role and clinical applications of exosomes in cancer drug resistance

Fra-1 affects chemotherapy sensitivity by inhibiting ferroptosis in gastric cancer cells

Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity

HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond

Mechanism of ferroptosis resistance in cancer cells

Breast cancer cell resistance to hormonal and targeted therapeutics is correlated with the inactivation of the NR6A1 axis

The emerging role of GLP-1 receptor agonists in treating or preventing cancer

Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment

CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma - a short report

Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer

Ovarian tumor microenvironment contributes to tumor progression and chemoresistance

Mitochondrial genome variability and metabolic alterations reveal new biomarkers of resistance in testicular germ cell tumors

Mechanisms of immunotherapy resistance in small cell lung cancer

Actions for 0 selected articles

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/